The Secretary must review whether payment arrangements match fair market value
What the document says“The Secretary, in consultation with the Office of the Inspector General, shall review whether remuneration under such arrangements is consistent with fair market value (as specified by the Secretary) through reviews and assessments of such remuneration, as determined appropriate.”
Parts of the payment arrangements between managers or their affiliates and other entities in the dispensing or use of part D drugs, including sponsors, manufacturers and pharmacies, are subject to review by the Secretary in consultation with the Office of the Inspector General. The Secretary and that Office must review whether the payments are consistent with fair market value.
What the document actually says“The Secretary, in consultation with the Office of the Inspector General, shall review whether remuneration under such arrangements is consistent with fair market value (as specified by the Secretary) through reviews and assessments of such remuneration, as determined appropriate.”
The health chief must check whether these payments match a fair market price. The department watchdog helps with the check.
A fee can be flat and still be far too large. Then it is income by another name. The review is meant to catch that.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.